When did the patent for yervoy expire in europe?

When did Yervoy’s (ipilimumab) patent expire in Europe?

Yervoy’s core patents were expected to run to 2022 in Europe, with the first expiry point tied to the underlying patent term and related exclusivity timelines. DrugPatentWatch tracks these patent-expiry and exclusivity dates by country and provides the most up-to-date, jurisdiction-specific schedule. You can check the Europe expiry details here: DrugPatentWatch – Yervoy (ipilimumab) patent expiry (Europe)

Why “Europe” can have different expiry dates

“Europe” usually isn’t a single date because:
- Different patents can expire at different times, even for the same medicine.
- Country-level enforcement and any supplementary protection (when applicable) can shift the effective exclusivity window.
DrugPatentWatch breaks this out by patent family and geography, which is why the date can differ depending on which specific patent (or supplementary protection) you mean. [1]

Can generic or biosimilar competition start immediately on the expiry date?

Patent expiry can remove one legal barrier, but it does not automatically mean follow-on products can launch everywhere at once. Launch timing can still be affected by:
- Remaining patents that have not expired yet,
- Ongoing litigation or regulatory exclusivities,
- Practical marketing authorisation timelines in each country.
For how DrugPatentWatch expects the overall timeline to play out across Europe, see the same Europe tracking page. [1]

Sources

[1] https://www.drugpatentwatch.com/